BMRN vs. CAH: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BMRN and CAH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BMRN | CAH |
|---|---|---|
| Company Name | BioMarin Pharmaceutical Inc. | Cardinal Health, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Providers & Services |
| Market Capitalization | 10.50 billion USD | 49.36 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | July 26, 1999 | August 4, 1983 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BMRN and CAH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BMRN | CAH |
|---|---|---|
| 5-Day Price Return | 3.91% | -0.03% |
| 13-Week Price Return | -4.88% | 37.27% |
| 26-Week Price Return | -8.45% | 38.52% |
| 52-Week Price Return | -17.90% | 63.86% |
| Month-to-Date Return | 2.17% | 7.65% |
| Year-to-Date Return | -16.74% | 73.64% |
| 10-Day Avg. Volume | 2.36M | 2.79M |
| 3-Month Avg. Volume | 2.29M | 2.38M |
| 3-Month Volatility | 26.60% | 36.97% |
| Beta | 0.27 | 0.65 |
Profitability
Return on Equity (TTM)
BMRN
8.84%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
BMRN’s Return on Equity of 8.84% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.
CAH
37.17%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
CAH’s Return on Equity of 37.17% is exceptionally high, placing it well beyond the typical range for the Health Care Providers & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
BMRN
16.82%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
BMRN’s Net Profit Margin of 16.82% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
CAH
0.68%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
Falling into the lower quartile for the Health Care Providers & Services industry, CAH’s Net Profit Margin of 0.68% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
Operating Profit Margin (TTM)
BMRN
19.89%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
BMRN’s Operating Profit Margin of 19.89% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
CAH
1.01%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
CAH’s Operating Profit Margin of 1.01% is in the lower quartile for the Health Care Providers & Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
Profitability at a Glance
| Symbol | BMRN | CAH |
|---|---|---|
| Return on Equity (TTM) | 8.84% | 37.17% |
| Return on Assets (TTM) | 7.13% | 3.11% |
| Net Profit Margin (TTM) | 16.82% | 0.68% |
| Operating Profit Margin (TTM) | 19.89% | 1.01% |
| Gross Profit Margin (TTM) | 81.32% | 3.66% |
Financial Strength
Current Ratio (MRQ)
BMRN
4.83
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
BMRN’s Current Ratio of 4.83 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
CAH
0.96
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
CAH’s Current Ratio of 0.96 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
BMRN
0.10
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
BMRN’s Debt-to-Equity Ratio of 0.10 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
CAH
5.65
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
With a Debt-to-Equity Ratio of 5.65, CAH operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
BMRN
-21.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
BMRN has a negative Interest Coverage Ratio of -21.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
CAH
10.77
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
CAH’s Interest Coverage Ratio of 10.77 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | BMRN | CAH |
|---|---|---|
| Current Ratio (MRQ) | 4.83 | 0.96 |
| Quick Ratio (MRQ) | 3.10 | 0.46 |
| Debt-to-Equity Ratio (MRQ) | 0.10 | 5.65 |
| Interest Coverage Ratio (TTM) | -21.18 | 10.77 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BMRN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
CAH
1.00%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
CAH’s Dividend Yield of 1.00% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
BMRN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
CAH
31.03%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
CAH’s Dividend Payout Ratio of 31.03% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | BMRN | CAH |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 31.03% |
Valuation
Price-to-Earnings Ratio (TTM)
BMRN
20.17
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
BMRN’s P/E Ratio of 20.17 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
CAH
30.91
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
CAH’s P/E Ratio of 30.91 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
BMRN
3.39
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
In the lower quartile for the Biotechnology industry, BMRN’s P/S Ratio of 3.39 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
CAH
0.21
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
In the lower quartile for the Health Care Providers & Services industry, CAH’s P/S Ratio of 0.21 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
BMRN
1.72
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
BMRN’s P/B Ratio of 1.72 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
CAH
14.54
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
At 14.54, CAH’s P/B Ratio is at an extreme premium to the Health Care Providers & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | BMRN | CAH |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 20.17 | 30.91 |
| Price-to-Sales Ratio (TTM) | 3.39 | 0.21 |
| Price-to-Book Ratio (MRQ) | 1.72 | 14.54 |
| Price-to-Free Cash Flow Ratio (TTM) | 12.71 | 9.96 |